CSPC Pharmaceutical Group Limited
CSPCY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.53 | -7.43 | 1.62 | -1.86 |
| FCF Yield | 3.45% | 2.67% | 5.17% | 2.87% |
| EV / EBITDA | 6.92 | 8.70 | 9.69 | 9.81 |
| Quality | ||||
| ROIC | 12.61% | 17.20% | 19.99% | 21.83% |
| Gross Margin | 69.97% | 70.51% | 64.91% | 74.51% |
| Cash Conversion Ratio | 0.98 | 0.57 | 1.25 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.11% | 0.40% | 5.73% | 10.90% |
| Free Cash Flow Growth | -18.81% | -53.39% | 70.40% | -54.98% |
| Safety | ||||
| Net Debt / EBITDA | -0.91 | -1.33 | -1.27 | -0.99 |
| Interest Coverage | 130.74 | 296.58 | 304.66 | 999.87 |
| Efficiency | ||||
| Inventory Turnover | 2.96 | 3.25 | 3.47 | 3.27 |
| Cash Conversion Cycle | 137.88 | 124.93 | 101.91 | 114.70 |